Heart Failure in Rheumatic Disease

References

1. • van Riet E.E.S.
   • Hoes A.W.
   • Wagenaar K.P.
   • et al.
   Comment on “Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review.
   Eur J Heart Fail. 2016; 18: 242-252
   View in Article

   • Google Scholar
2. • Heidenreich P.A.
   • Bozkurt B.
   • Aguilar D.
   • et al.
   2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
   J Am Coll Cardiol. 2022; 79https://doi.org/10.1016/j.jacc.2021.12.012
   View in Article

   • Google Scholar
3. • McDonagh T.A.
   • Metra M.
   • Adamo M.
   • et al.
   2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
   Eur Heart J. 2021; 42: 3599-3726
   View in Article

   • Google Scholar
4. • Mantel Ä.
   • Holmqvist M.
   • Andersson D.C.
   • et al.
   Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure.
   J Am Coll Cardiol. 2017; 69: 1275-1285
   View in Article

   • Google Scholar
5. • Løgstrup B.B.
   • Ellingsen T.
   • Pedersen A.B.
   • et al.
   Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study.
   Eur J Clin Invest. 2018; 48: 1-8
   View in Article

   • Google Scholar
6. • Crowson C.S.
   • Nicola P.J.
   • Kremers H.M.
   • et al.
   How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?.
   Arthritis Rheum. 2005; 52: 3039-3044
   View in Article

   • Google Scholar
7. • Nicola P.J.
   • Maradit-Kremers H.
   • Roger V.L.
   • et al.
   The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years.
   Arthritis Rheum. 2005; 52: 412-420
   View in Article

   • Google Scholar
8. • Løgstrup B.B.
   • Ellingsen T.
   • Pedersen A.B.
   • et al.
   Heart Failure and Ischemic Heart Disease in Patients With Rheumatoid Arthritis.
   J Am Coll Cardiol. 2017; 70: 3069-3071
   View in Article

   • Google Scholar
9. • Ferreira M.B.
   • Fonseca T.
   • Costa R.
   • et al.
   Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study.
   Eur J Intern Med. 2021; 85: 41-49
   View in Article

   • Google Scholar
10. • Solomon D.H.
    • Karlson E.W.
    • Rimm E.B.
    • et al.
    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
    Circulation. 2003; 107: 1303-1307
    View in Article

    • Google Scholar
11. • Peters M.J.L.
    • Van Halm V.P.
    • Voskuyl A.E.
    • et al.
    Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study.
    Arthritis Care Res. 2009; 61: 1571-1579
    View in Article

    • Google Scholar
12. • Khalid Y.
    • Dasu N.
    • Shah A.
    • et al.
    Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis.
    ESC Hear Fail. 2020; 7: 3745-3753
    View in Article

    • Google Scholar
13. • Baniaamam M.
    • Paulus W.J.
    • Blanken A.B.
    • et al.
    The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review.
    Expert Opin Biol Ther. 2018; 18: 585-594
    View in Article

    • Google Scholar
14. • Solomon D.H.
    • Greenberg J.
    • Curtis J.R.
    • et al.
    Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry study.
    Arthritis Rheumatol. 2015; 67: 1995-2003
    View in Article

    • Google Scholar
15. • Nissen S.E.
    • Yeomans N.D.
    • Solomon D.H.
    • et al.
    Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
    N Engl J Med. 2016; 375: 2519-2529
    View in Article

    • Google Scholar
16. • Moder K.G.
    • Miller T.D.
    • Tazelaar H.D.
    Cardiac involvement in systemic lupus erythematosus.
    Mayo Clin Proc. 1999; 74: 275-284
    View in Article

    • Google Scholar
17. • Kim C.H.
    • Al-Kindi S.G.
    • Jandali B.
    • et al.
    Incidence and risk of heart failure in systemic lupus erythematosus.
    Heart. 2017; 103: 227-233
    View in Article

    • Google Scholar
18. • Chen S.K.
    • Barbhaiya M.
    • Fischer M.A.
    • et al.
    Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.
    Semin Arthritis Rheum. 2019; 49: 389-395
    View in Article

    • Google Scholar
19. • Dhakal B.P.
    • Kim C.H.
    • Al-Kindi S.G.
    • et al.
    Heart failure in systemic lupus erythematosus.
    Trends Cardiovasc Med. 2018; 28: 187-197
    View in Article

    • Google Scholar
20. • Yafasova A.
    • Fosbøl E.L.
    • Schou M.
    • et al.
    Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus.
    J Am Coll Cardiol. 2021; 77: 1717-1727
    View in Article

    • Google Scholar
21. • Manzi S.
    • Meilahn E.N.
    • Rairie J.E.
    • et al.
    Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study.
    Am J Epidemiol. 1997; 145: 408-415
    View in Article

    • Google Scholar
22. • Jonsson H.
    • Nived O.
    • Sturfelt G.
    Outcome in Systemic Lupus Erythematosus - A prospective Study of Patients from a Defined Population.
    Medicne. 1989; 68: 141-150
    View in Article

    • Google Scholar
23. • Bae K.H.
    • Hong J.B.
    • Choi Y.J.
    • et al.
    Association of Congestive Heart Failure and Death with Ankylosing Spondylitis : A Nationwide Longitudinal Cohort Study in Korea.
    J Korean Neurosurg Soc. 2019; 62: 217-224
    View in Article

    • Google Scholar
24. • Han C.
    • Robinson D.W.J.
    • Hackett M.V.
    • et al.
    Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    J Rheumatol. 2006; 33: 2167-2172
    View in Article

    • Google Scholar
25. • Castaneda S.
    • Gonzalez-Juanatey C.
    • Gonzalez-Gay M.A.
    Inflammatory Arthritis and Heart Disease.
    Curr Pharm Des. 2018; 24: 262-280
    View in Article

    • Google Scholar
26. • Heslinga S.C.
    • Van Dongen C.J.
    • Konings T.C.
    • et al.
    Diastolic left ventricular dysfunction in ankylosing spondylitis--a systematic review and meta-analysis.
    Semin Arthritis Rheum. 2014; 44: 14-19
    View in Article

    • Google Scholar
27. • Ahlehoff O.
    • Gislason G.H.
    • Charlot M.
    • et al.
    Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study.
    J Intern Med. 2011; 270: 147-157
    View in Article

    • Google Scholar
28. • Koppikar S.
    • Colaco K.
    • Harvey P.
    • et al.
    Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study.
    Arthritis Care Res (Hoboken). 2021; 74: 1244-1253
    View in Article

    • Google Scholar
29. • Khalid U.
    • Ahlehoff O.
    • Gislason G.H.
    • et al.
    Psoriasis and risk of heart failure: a nationwide cohort study.
    Eur J Heart Fail. 2014; 16: 743-748
    View in Article

    • Google Scholar
30. • Kondratiouk S.
    • Udaltsova N.
    • Klatsky A.L.
    Associations of psoriatic arthritis and cardiovascular conditions in a large population.
    Perm J. 2008; 12: 4-8
    View in Article

    • Google Scholar
31. • Gladman D.D.
    • Ang M.
    • Su L.
    • et al.
    Cardiovascular morbidity in psoriatic arthritis.
    Ann Rheum Dis. 2009; 68: 1131-1135
    View in Article

    • Google Scholar
32. • Kibari A.
    • Cohen A.D.
    • Gazitt T.
    • et al.
    Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study.
    Clin Rheumatol. 2019; 38: 2069-2075
    View in Article

    • Google Scholar
33. • Polachek A.
    • Touma Z.
    • Anderson M.
    • et al.
    Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.
    Arthritis Care Res. 2017; 69: 67-74
    View in Article

    • Google Scholar
34. • Lottmann K.
    • Chen X.
    • Schädlich P.K.
    Association between gout and all-cause as well as cardiovascular mortality: A systematic review.
    Curr Rheumatol Rep. 2012; 14: 195-203
    View in Article

    • Google Scholar
35. • Colantonio L.D.
    • Saag K.G.
    • Singh J.A.
    • et al.
    Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study.
    Arthritis Res Ther. 2020; 22: 86
    View in Article

    • Google Scholar
36. • Huang H.
    • Huang B.
    • Li Y.
    • et al.
    Uric acid and risk of heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2014; 16: 15-24
    View in Article

    • Google Scholar
37. • Krishnan E.
    Gout and the risk for incident heart failure and systolic dysfunction.
    BMJ Open. 2012; 2: 1-8
    View in Article

    • Google Scholar
38. • Wu X.
    • Jian G.
    • Tang Y.
    • et al.
    Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.
    Nutr Metab Cardiovasc Dis. 2020; 30: 666-673
    View in Article

    • Google Scholar
39. • Bartels C.M.
    • Kind A.J.H.
    • Everett C.
    • et al.
    Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis.
    Arthritis Rheum. 2011; 63: 1221-1230
    View in Article

    • Google Scholar
40. • Toms T.E.
    • Panoulas V.F.
    • Douglas K.M.J.
    • et al.
    Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk?.
    Ann Rheum Dis. 2010; 69: 683-688
    View in Article

    • Google Scholar
41. • Alemao E.
    • Cawston H.
    • Bourhis F.
    • et al.
    Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis.
    Rheumatol (United Kingdom). 2017; 56: 777-786
    View in Article

    • Google Scholar
42. • Esdaile J.M.
    • Abrahamowicz M.
    • Grodzicky T.
    • et al.
    Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.
    Arthritis Rheum. 2001; 44: 2331-2337
    View in Article

    • Google Scholar
43. • Van Breukelen-van der Stoep D.F.
    • Van Zeben D.
    • Klop B.
    • et al.
    Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis.
    Rheumatol (United Kingdom). 2016; 55: 1210-1216
    View in Article

    • Google Scholar
44. • Svensson A.L.
    • Christensen R.
    • Persson F.
    • et al.
    Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: Protocol for a multicentre randomised controlled trial.
    BMJ Open. 2016; 6https://doi.org/10.1136/bmjopen-2015-009134
    View in Article

    • Google Scholar
45. • Paulus W.J.
    • Tschöpe C.
    A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    J Am Coll Cardiol. 2013; 62: 263-271
    View in Article

    • Google Scholar
46. • Westermann D.
    • Lindner D.
    • Kasner M.
    • et al.
    Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.
    Circ Hear Fail. 2011; 4: 44-52
    View in Article

    • Google Scholar
47. • Van Linthout S.
    • Tschöpe C.
    Inflammation – Cause or Consequence of Heart Failure or Both?.
    Curr Heart Fail Rep. 2017; 14: 251-265
    View in Article

    • Google Scholar
48. • Porrello Enzo
    • Mahmoud Ahmed
    • Simpson Emma
    • et al.
    Transient Regenerative Potential of the Neonatal Mouse Heart.
    Science. 2011; 331 (.Transient): 1078-1080
    View in Article

    • Google Scholar
49. • Farache Trajano L.
    • Smart N.
    Immunomodulation for optimal cardiac regeneration: insights from comparative analyses.
    Npj Regen Med. 2021; 6: 1-11
    View in Article

    • Google Scholar
50. • Bansal Shyam S.
    • Ismahil Mohamad
    • Goel Mehek
    • et al.
    Activated T-Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.
    Circ Hear Fail. 2017; 10 (Activated): e003688
    View in Article

    • Google Scholar
51. • Dolejsi T.
    • Delgobo M.
    • Schuetz T.
    • et al.
    Adult T-cells impair neonatal cardiac regeneration.
    Eur Heart J. 2022; https://doi.org/10.1093/eurheartj/ehac153
    View in Article

    • Google Scholar
52. • Garbern J.C.
    • Lee R.T.
    Heart regeneration: 20 years of progress and renewed optimism.
    Dev Cell. 2022; 57: 424-439
    View in Article

    • Google Scholar
53. • Torre-Amione G.
    • Kapadia S.
    • Benedict C.
    • et al.
    Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD).
    J Am Coll Cardiol. 1996; 27: 1201-1206
    View in Article

    • Google Scholar
54. • Deswal A.
    • Petersen N.J.
    • Feldman A.M.
    • et al.
    Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST).
    Circulation. 2001; 103: 2055-2059
    View in Article

    • Google Scholar
55. • Libby P.
    • Ridker P.M.
    • Hansson G.K.
    Inflammation in Atherosclerosis. From Pathophysiology to Practice.
    J Am Coll Cardiol. 2009; 54: 2129-2138
    View in Article

    • Google Scholar
56. • Libby P.
    Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis.
    Am J Med. 2008; 121https://doi.org/10.1016/j.amjmed.2008.06.014
    View in Article

    • Google Scholar
57. • Elenkov I.J.
    • Wilder R.L.
    • Chrousos G.P.
    • et al.
    The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
    Pharmacol Rev. 2000; 52: 595-638
    View in Article

    • Google Scholar
58. • Ahlehoff O.
    • Gislason G.H.
    • Jorgensen C.H.
    • et al.
    Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study.
    Eur Heart J. 2012; 33: 2054-2064
    View in Article

    • Google Scholar
59. • Lazzerini P.E.
    • Capecchi P.L.
    • Laghi-Pasini F.
    Assessing QT interval in patients with autoimmune chronic inflammatory diseases: Perils and pitfalls.
    Lupus Sci Med. 2016; 3: 1-5
    View in Article

    • Google Scholar
60. • Santos R.C.
    • Figueiredo V.N.
    • Martins L.C.
    • et al.
    Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure.
    Rev Assoc Med Bras. 2012; 58: 698-702
    View in Article

    • Google Scholar
61. • Mann D.L.
    • McMurray J.J.V.
    • Packer M.
    • et al.
    Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
    Circulation. 2004; 109: 1594-1602
    View in Article

    • Google Scholar
62. • Chung C.P.
    • Giles J.T.
    • Petri M.
    • et al.
    Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: Comparison with control subjects from the multi-ethnic study of atherosclerosis.
    Semin Arthritis Rheum. 2012; 41: 535-544
    View in Article

    • Google Scholar
63. • Lv S.
    • Han M.
    • Yi R.
    • et al.
    Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis.
    Int J Clin Pract. 2014; 68: 520-528
    View in Article

    • Google Scholar
64. • Fakharian A.
    • Barati S.
    • Mirenayat M.
    • et al.
    Evaluation of adalimumab effects in managing severe cases of COVID-19 : A randomized controlled trial.
    Int Immunopharmacol. 2021; 99: 107961
    View in Article

    • Google Scholar
65. • Everett B.M.
    • Siddiqi H.K.
    Heart Failure, the Inflammasome, and Interleukin-1β: Prognostic and Therapeutic?.
    J Am Coll Cardiol. 2019; 73: 1026-1028
    View in Article

    • Google Scholar
66. • Ridker P.M.
    • Everett B.M.
    • Thuren T.
    • et al.
    Antiinflammatory therapy with canakinumab for atherosclerotic disease.
    N Engl J Med. 2017; 377: 1119-1131
    View in Article

    • Google Scholar
67. • Buckley Leo
    • Carbone Salvatore
    • Trankle Cory
    • et al.
    Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post-Hoc Pooled Analysis of Two Clinical Trials.
    J Cardiovasc Pharmacol. 2018; 72 (Effect): 68-70
    View in Article

    • Google Scholar
68. • Kobayashi H.
    • Kobayashi Y.
    • Giles J.T.
    • et al.
    Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: Assessed using 3.0 tesla cardiac magnetic resonance imaging.
    J Rheumatol. 2014; 41: 1916-1921
    View in Article

    • Google Scholar
69. • Yokoe I.
    • Kobayashi H.
    • Kobayashi Y.
    • et al.
    Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms.
    Scand J Rheumatol. 2018; 47: 364-370
    View in Article

    • Google Scholar
70. • Yano T.
    • Osanami A.
    • Shimizu M.
    • et al.
    Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting.
    ESC Hear Fail. 2019; 6: 894-897
    View in Article

    • Google Scholar
71. • Meyer M.A.S.
    • Wiberg S.
    • Grand J.
    • et al.
    Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial.
    Circulation. 2021; 143: 1841-1851
    View in Article

    • Google Scholar
72. • Torre-Amione G.
    • Anker S.D.
    • Bourge R.C.
    • et al.
    Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.
    Lancet (London, England). 2008; 371: 228-236
    View in Article

    • Google Scholar
73. • Torre-Amione G.
    • Sestier F.
    • Radovancevic B.
    • et al.
    Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial.
    J Am Coll Cardiol. 2004; 44: 1181-1186
    View in Article

    • Google Scholar
74. • Fishel R.S.
    • Eisenberg S.
    • Shai S.Y.
    • et al.
    Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle.
    Hypertens (Dallas, Tex 1979). 1995; 25: 343-349
    View in Article

    • Google Scholar
75. • Garg R.
    • Yusuf S.
    Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
    JAMA. 1995; 273: 1450-1456
    View in Article

    • Google Scholar
76. • McMurray J.J.V.
    • Packer M.
    • Desai A.S.
    • et al.
    Angiotensin-neprilysin inhibition versus enalapril in heart failure.
    N Engl J Med. 2014; 371: 993-1004
    View in Article

    • Google Scholar
77. • Ò Miró
    • Takagi K.
    • Gayat E.
    • et al.
    CORT-AHF Study: Effect on Outcomes of Systemic Corticosteroid Therapy During Early Management Acute Heart Failure.
    JACC Heart Fail. 2019; 7: 834-845
    View in Article

    • Google Scholar
78. • Ain Q.U.
    • Batool M.
    • Choi S.
    TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches.
    Molecules. 2020; 25https://doi.org/10.3390/molecules25030627
    View in Article

    • Google Scholar
79. • Champion S.
    • Lapidus N.
    • Cherié G.
    • et al.
    Pentoxifylline in heart failure: A meta-analysis of clinical trials.
    Cardiovasc Ther. 2014; 32: 159-162
    View in Article

    • Google Scholar
80. • Aukrust P.
    • Yndestad A.
    • Damås J.K.
    • et al.
    Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.
    Autoimmun Rev. 2004; 3: 221-227
    View in Article

    • Google Scholar
81. • Moreira D.M.
    • Vieira J.L.
    • Mascia Gottschall C.A.
    The Effects of METhotrexate Therapy on the Physical Capacity of Patients With ISchemic Heart Failure: A Randomized Double-Blind, Placebo-Controlled Trial (METIS Trial).
    J Card Fail. 2009; 15: 828-834
    View in Article

    • Google Scholar
82. • Van Tassell B.W.
    • Canada J.
    • Carbone S.
    • et al.
    Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
    Circ Hear Fail. 2017; 10: 1-11
    View in Article

    • Google Scholar
83. • Van Tassell B.W.
    • Arena R.
    • Biondi-Zoccai G.
    • et al.
    Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).
    Am J Cardiol. 2014; 113: 321-327
    View in Article

    • Google Scholar
84. • Trankle C.R.
    • Canada J.M.
    • Cei L.
    • et al.
    Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.
    Am J Cardiol. 2018; 122: 1366-1370
    View in Article

    • Google Scholar
85. • Chung E.S.
    • Packer M.
    • Lo K.H.
    • et al.
    Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH.
    Circulation. 2003; 107: 3133-3140
    View in Article

    • Google Scholar
86. • Givertz M.M.
    • Anstrom K.J.
    • Redfield M.M.
    • et al.
    Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
    Circulation. 2015; 131: 1763-1771
    View in Article

    • Google Scholar
87. • Hare J.M.
    • Mangal B.
    • Brown J.
    • et al.
    Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
    J Am Coll Cardiol. 2008; 51: 2301-2309
    View in Article

    • Google Scholar
88. • Tang L.
    • Wang H.
    • Ziolo M.T.
    Targeting NOS as a therapeutic approach for heart failure.
    Pharmacol Ther. 2014; 142: 306-315
    View in Article

    • Google Scholar
89. • Tavazzi L.
    • Maggioni A.P.
    • Marchioli R.
    • et al.
    Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England). 2008; 372: 1231-1239
    View in Article

    • Google Scholar
90. • Kjekshus J.
    • Apetrei E.
    • Barrios V.
    • et al.
    Rosuvastatin in older patients with systolic heart failure.
    N Engl J Med. 2007; 357: 2248-2261
    View in Article

    • Google Scholar
91. • Deftereos S.
    • Giannopoulos G.
    • Panagopoulou V.
    • et al.
    Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study.
    JACC Heart Fail. 2014; 2: 131-137
    View in Article

    • Google Scholar
92. • Wohlford G.F.
    • Van Tassell B.W.
    • Billingsley H.E.
    • et al.
    Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020; 77: 49-60
    View in Article

    • Google Scholar